ZYBERNO
Stock Report
Updated Sep 1, 2026

ACTINIUM PHARMACEUTICALS, INC. (ATNM)

Healthcare • NYSE

$1.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
50.0/100
AVERAGE BUSINESS
ACTINIUM PHARMACEUTICALS, INC. (ATNM) scores 50/100 — decent metrics but limited evidence of durable competitive advantage.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
+17.7%
Market Underestimates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):EXCELLENT (83.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.07x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):NEUTRAL (243.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ACTINIUM PHARMACEUTICALS, INC. (ATNM) stock report — Zyberno Score 50/100 (AVERAGE BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, ACTINIUM PHARMACEUTICALS, INC. (ATNM) shows a Brina Gap of +17.7%, which strengthens the case: based on the company's ROIC (243.9%) and reinvestment rate (-1.0%), the business can fundamentally grow at -2.4% — but the current enterprise value implies the market expects -20.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.02
Market Cap:$32.03M

Valuation Multiples (4)

P/B Ratio:1.06x
P/S Ratio:355.86x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$4.66M
Ev Ebitda Ratio:0.49x

Price Action & Momentum (3)

Momentum Percentile:17 / 100
% of 52-Week High:56.7%
B. Profitability Assessment

Return Metrics (7)

ROA:23.4%
Reinvestment Rate:-1.0%
Fundamental Growth Rate (g):-2.4%
Market-Implied Growth Rate:-20.0%

Margin Analysis (1)

Ebitda Margin:10,614.4%

Yield Metrics (2)

Earnings Yield:$32.41
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:784.6%
Latest Earnings Filed:2026-08-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):67.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.08x
Quick Ratio:4.08x
Cash Ratio:3.94x

Leverage Analysis (3)

Debt To Equity Ttm:0.07x
Debt-to-Equity Ratio:0.07x
Debt To Ebitda:0.95x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:28,480,000.00
Cash And Cash Equivalents:36,473,000.00
Long Term Debt:$595.00K
Net Debt:-$27.36M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $90.00K
Linear Growth: 67.7%
📊 Click to view full ATNM Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00$9.56M

Bottom Line Performance (3)

$11.31M
Income Before Tax:-$33.29M
Ebitda Ttm:9,553,000.00

Operating Expenses (5)

Operating Expenses:25,534,000.00
R And D Expense:18,123,000.00
Sga Expense:7,411,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:51.8%
Sga To Revenue Percentage:21.2%
Ebitda Margin:10,614.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$40.16M
Current Assets:$37.74M
Ppe Net:700,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:9,855,000.00
Current Liabilities:9,260,000.00
Long Term Debt:$595.00K
Short Term Debt:$8.51M

Equity & Capital (3)

Equity:$30.30M
Retained Earnings:-$387.33M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:8,514,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:11,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$22.88M-$24.68M

Investment Activities (1)

Investing Cash Flow:-$2.00K

Financing Activities (3)

Financing Cash Flow:-$3.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:29,255,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:-3,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.35
$0.35
Earnings Per Share Ttm:$0.36

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.78

Book Value & Capital (2)

Book Value Per Share:$0.97
Cash Per Share:1.16

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:34,529.00
Cash Conversion Cycle:-36,527.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-1.0%
Fundamental Growth Rate (g):-2.4%
Market-Implied Growth Rate:-20.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):67.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-41.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:ATNM
Company Name:ACTINIUM PHARMACEUTICALS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:31.40M
Shares Outstanding Basic:31.40M
Shares Outstanding Diluted:31.41M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 07:22:45 UTC
Data Timestamp:2026-08-20T19:19:05.248042
Scroll to Top